Pathios Therapeutics appoints new Non-Executive Director
Published on 30 November 2022
Milton Park-based Pathios Therapeutics, a biotech company focused on developing first-in-class therapies for cancer, has announced that Jeanmarie Guenot PhD has been appointed as a non-executive director to the company’s board of directors.
Dr Guenot brings more than 30 years of experience in the pharmaceutical and biotechnology industries, having worked in venture capital, as well as at public and private companies in roles spanning executive management, corporate development and research and development.
Dr Guenot is currently the Founder, President and Chief Executive Officer of Toreador Therapeutics, a preclinical stage company discovering and developing bispecific antibody therapeutics for the treatment of cancer.
In 2013, she founded Amphivena Therapeutics and served as the company’s President and Chief Executive Officer through the end of 2019. During her time with Amphivena, Dr Guenot oversaw the closing of a $62 million Series C financing, as well as the advancement of the company’s lead therapeutic candidate, a novel T cell engager in clinical trials for acute myeloid leukaemia and myelodysplastic syndrome, into Phase 1 clinical trials for the treatment of solid tumours.
In 2015, while still leading Amphivena, she founded and became the President and Chief Executive Officer of Harpoon Therapeutics (NASDAQ: HARP), a company developing half-life extended and conditionally-activated T cell engagement therapeutics for the treatment of cancer. In 2016, Dr Guenot spun out Maverick Therapeutics from Harpoon and executed a strategic build-to-buy transaction with Takeda. This deal, which included a $125 million upfront option and R&D funding, and up to $525 million in option exercise and earnouts, was exercised in 2021.
Stuart Hughes PhD, Chief Executive Officer at Pathios Therapeutics, said: “We are delighted to welcome Jeanmarie to Pathios to help us to deliver on the promise of targeting GPR65 as a critical innate immune checkpoint in solid tumours.
“Her extensive experience in both corporate management and R&D leadership make her perfectly suited to support Pathios in the next phase of our mission to advance our GPR65 small-molecule inhibitors toward clinical development.”
Dr Jeanmarie Guenot PhD, appointed Non-Executive Director at Pathios Therapeutics, said: “I am honoured to join the board of Pathios Therapeutics and help support the ground-breaking science the company is advancing in the area of immune checkpoint inhibitors.
“The company has already compiled a compelling preclinical data package for its small molecule inhibitors of GPR65 that offers strong rationale for advancing the program into the clinic to address major unmet medical needs for cancer patients.
“I look forward to working with the Pathios board and executive team at this pivotal time and am excited to contribute to the continued development of the company’s first-in-class therapies.”
To find out more about Pathios Therapeutics and its work, please visit: pathiostherapeutics.com